A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success.

Unité de recherche en Génétique humaine, Centre Hospitalier de l'Université Laval, Ste-Foy, Québec, Canada.
American Journal of Transplantation (Impact Factor: 6.19). 11/2007; 7(10):2247-59. DOI: 10.1111/j.1600-6143.2007.01927.x
Source: PubMed

ABSTRACT Myogenic precursor cell (MPC) transplantation is a good strategy to introduce dystrophin expression in muscles of Duchenne muscular dystrophy (DMD) patients. Insulin-like growth factor (IGF-1) promotes MPC activities, such as survival, proliferation, migration and differentiation, which could enhance the success of their transplantation. Alternative splicing of the IGF-1 mRNA produces different muscle isoforms. The mechano growth factor (MGF) is an isoform, especially expressed after a mechanical stress. A 24 amino acids peptide corresponding to the C-terminal part of the MGF E domain (MGF-Ct24E peptide) was synthesized. This peptide had been shown to enhance the proliferation and delay the terminal differentiation of C(2)C(12) myoblasts. The present study showed that the MGF-Ct24E peptide improved human MPC transplantation by modulating their proliferation and differentiation. Indeed, intramuscular or systemic delivery of this synthetic peptide significantly promoted engraftment of human MPCs in mice. In vitro experiments demonstrated that the MGF-Ct24E peptide enhanced MPC proliferation by a different mechanism than the binding to the IGF-1 receptor. Moreover, MGF-Ct24E peptide delayed human MPC differentiation while having no outcome on survival. Those combined effects are probably responsible for the enhanced transplantation success. Thus, the MGF-Ct24E peptide is an interesting agent to increase MPC transplantation success in DMD patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The human insulin-like growth factor-1 (IGF-1) gene gives rise to multiple, heterogeneous mRNA transcripts by alternative splicing, thus producing different IGF-1 isoforms. The mechano growth factor (MGF) is an IGF-1 isoform that was found to be markedly up-regulated in exercised or damaged muscle. The specific E domain of the MGF splice variant may act as an independent growth factor. The aim of the present study was to characterize a rabbit antihuman MGF polyclonal antibody. New-Zealand rabbits were immunized by injections of a purified synthetic peptide corresponding to the last 24 amino acids of the human C-terminal of the MGF E domain. Western blotting and immunohistochemical techniques were used to characterize the specificity of the polyclonal anti-MGF antiserum. The anti-MGF antiserum was found to recognize the MGF E-peptide and not the common part of the IGF-1 isoforms, i.e. the mature IGF-1 peptide. Furthermore, it specifically bound to the MGF protein in human skeletal and in rat cardiac muscle, apparently due to the considerable homology between the human and rat MGF E-peptide sequences. Immunostaining analysis showed that this polyclonal anti-MGF antibody was able to detect MGF in human muscle and in rat cardiomyocytes and vessels' smooth muscle cells. We conclude that this rabbit polyclonal anti-human/rat MGF antibody could become a valuable tool in the study of IGF-1 isoforms in human and rat tissues.
    In vivo (Athens, Greece) 01/2008; 22(1):27-35. · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mechano-growth factor (MGF), a splice variant of insulin-like growth factor I (IGF-I), was discovered by Goldspink and colleagues in 1996, since which many studies have implicated MGF as an important local tissue repair factor. While the short 24-amino acid C-terminal peptide of MGF (MGF-Ct24E) has a variety of biological activities, its role in bone formation has not yet been clarified. Accordingly, the aim of this study was to investigate the role of MGF-Ct24E on the proliferation, differentiation and mineralization of rat calvarial osteoblasts. Interestingly, while MGF-Ct24E significantly increased the proliferation and retarded the differentiation of osteoblasts during the first three days, prolonged treatment with MGF-Ct24E for up to three weeks promoted cell differentiation. In order to determine the molecular mechanisms behind this plurality, we carried out global transcriptional profiling of osteoblasts in response to MGF-Ct24E and identified differentially expressed genes by bioinformatics analysis. Gene ontology (GO) analysis indicated that MGF-Ct24E enhanced the expression of genes associated with osteoblast proliferation and the cell cycle, and down-regulated genes involved with osteoblast differentiation, skeletal system and bone development. Moreover, KEGG pathway-based analysis indicated that MGF-Ct24E directly altered focal adhesion and cell cycle progression, in addition to regulating the actin cytoskeleton and gap junctions. In conclusion, MGF-Ct24E has a marked ability to increase bone formation by increasing cell proliferation and delaying cell differentiation during prophase, as well as by stimulating osteoblast differentiation during advanced stage. The mechanism of action of MGF-Ct24E during the initial stages of bone formation in vitro involves up-regulation of the expression of genes involved in proliferation and cell cycle progression, and the repression of differentiation-related genes.
    Biotechnology and Applied Biochemistry 08/2013; · 1.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Myopathies produce deficits in skeletal muscle function and, in some cases, literally progressive loss of skeletal muscles. The transplantation of cells able to differentiate into myofibers is an experimental strategy for the potential treatment of some of these diseases. AREAS COVERED: Among the two routes used to deliver cells to skeletal muscles, that is intramuscular and intravascular, this paper focuses on the intramuscular route due to our expertise and because it is the most used in animal experiments and the only tested so far in humans. Given the absence of recent reviews about clinical observations and the profusion based on mouse results, this review prioritizes observations made in humans and non-human primates. The review provides a vision of cell transplantation in myology centered on what can be learned from clinical trials and from preclinical studies in non-human primates and leading mouse studies. EXPERT OPINION: Experiments on myogenic cell transplantation in mice are essential to quickly identify potential treatments, but studies showing the possibility to scale up the methods in large mammals are indispensable to determine their applicability in humans and to design clinical protocols.
    Expert opinion on biological therapy 03/2011; 11(3):359-74. · 3.22 Impact Factor